Is an antiepileptic medication appropriate for a hospice patient who continues to have seizures despite lorazepam (Ativan)?

Yes, antisepileptic medication is absolutely appropriate and should be administered for seizures unresponsive to lorazepam in hospice patients.

For a hospice patient with active seizures despite lorazepam (Ativan), you should immediately administer a second-line antiepileptic drug to prevent progression to refractory status epilepticus and reduce suffering. The goal in hospice is comfort and quality of life, and uncontrolled seizures cause significant distress to both patients and families.

Recommended Second-Line Options

When benzodiazepines fail in status epilepticus, guidelines support several second-line agents 1:

First Choice: Levetiracetam (Keppra)

• Dose: 30-50 mg/kg IV load (typically 1,500-4,000 mg) at 100 mg/min 1
• Efficacy: 67-73% seizure cessation in benzodiazepine-refractory status epilepticus 1
• Advantages for hospice:
  • Minimal respiratory depression or hypotension 1
  • Can be given subcutaneously if IV access unavailable 2
  • Low sedation profile preserves consciousness and quality of life
  • Few drug interactions 3
  • Available in subcutaneous formulation for end-of-life care 2

Alternative: Valproate (Depacon)

• Dose: 20-30 mg/kg IV at 40 mg/min 1
• Efficacy: 68-88% seizure cessation 1
• Advantages: Can be given rapidly, no hypotension 1
• Disadvantages: Thrombocytopenia, liver toxicity concerns 1

Traditional Option: Phenytoin/Fosphenytoin

• Dose: 18-20 mg/kg (or PE/kg for fosphenytoin) 1
• Efficacy: 56-88% depending on study 1
• Disadvantages: Hypotension, cardiac dysrhythmias, slower administration 1
• Note: 95% of neurologists historically recommended this, but newer agents may be preferable 1

Hospice-Specific Considerations

Route of Administration

The FDA label for Ativan indicates that if seizures continue after initial lorazepam dosing (4 mg IV slowly), an additional 4 mg may be given after 10-15 minutes 4. However, if seizures persist despite adequate benzodiazepine dosing, progression to second-line agents is critical 4.

For patients without IV access:

• Subcutaneous levetiracetam: 250-4,000 mg/24 hours via syringe driver, 1:1 oral-to-subcutaneous conversion 2
• Buccal/sublingual benzodiazepines for maintenance 5
• Intranasal midazolam for acute breakthrough 5

Avoiding Excessive Sedation

A critical distinction in hospice care: seizure control does not require deep sedation. Levetiracetam specifically allows seizure management without causing the profound sedation seen with barbiturates or propofol 1, 2. This preserves patient awareness and quality of life during their final days.

When Sedation May Be Appropriate

If seizures remain refractory despite second-line agents AND the patient is actively dying with intractable symptoms, palliative sedation with midazolam or propofol may be considered after consultation with palliative care specialists 6. However, this represents a distinct clinical decision separate from treating status epilepticus.

Critical Pitfalls to Avoid

1. Underdosing lorazepam: The recommended dose is 0.1 mg/kg up to 4 mg 4. Doses less than 4 mg are associated with 87% progression to refractory status epilepticus versus 62% with full 4 mg dosing 7. Ensure adequate initial benzodiazepine dosing before declaring failure.

2. Assuming sedation is inevitable: Modern antiepileptics like levetiracetam provide seizure control without significant sedation 2, 3, allowing patients to remain comfortable yet conscious.

3. Delaying second-line therapy: Status epilepticus causes neurological damage and suffering. Waiting increases morbidity even in hospice patients 4, 8.

4. Forgetting alternative routes: When oral intake fails, subcutaneous levetiracetam or brivaracetam (150-300 mg/24 hours) can maintain seizure control without IV access 2, 3.

Clinical Algorithm

1. Confirm adequate lorazepam dosing: 4 mg IV (or 0.1 mg/kg) given slowly over 2 minutes 4
2. If seizures continue after 10-15 minutes: Give second 4 mg dose 4
3. If seizures persist: Immediately administer second-line agent:
   • Preferred: Levetiracetam 30-50 mg/kg IV (or subcutaneous if no IV access) 1, 2
   • Alternative: Valproate 20-30 mg/kg IV 1
4. Monitor: Airway patency, vital signs, seizure activity 4
5. For ongoing seizure risk: Continue maintenance antiepileptic via most appropriate route (oral, subcutaneous, or IV) 2, 5

The evidence strongly supports aggressive seizure management in hospice patients to maintain comfort and dignity, using agents that minimize sedation while maximizing seizure control 8, 9.